Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.

Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.

Bibliografske podrobnosti
Main Authors:	Pazianas, M, Abrahamsen, B
Format:	Journal article
Jezik:	English
Izdano:	2014

Podobne knjige/članki

Safety issues with bisphosphonate therapy for osteoporosis.
od: Suresh, E, et al.
Izdano: (2014)

Safety of bisphosphonates.
od: Pazianas, M, et al.
Izdano: (2011)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
od: Pazianas, M, et al.
Izdano: (2010)

Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
od: Pazianas, M, et al.
Izdano: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates.
od: Pazianas, M, et al.
Izdano: (2013)

Bisphosphonates and colon cancer: reply.
od: Pazianas, M, et al.
Izdano: (2013)

Bisphosphonates and colon cancer: Reply
od: Pazianas, M, et al.
Izdano: (2013)

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.
od: Abrahamsen, B, et al.
Izdano: (2013)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
od: Jiaqi Wu, et al.
Izdano: (2018-08-01)

Safety and efficacy of bisphosphonates in thalassemia patients with osteopenia/osteoporosis
od: Sujata Sharma, et al.
Izdano: (2023-04-01)

The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
od: Zaoqian Zheng, et al.
Izdano: (2020-09-01)

The art of treating osteoporosis: Bisphosphonates
od: Sergey Olegovich Mazurenko
Izdano: (2012-03-01)

Intravenous bisphosphonates for postmenopausal osteoporosis
od: Peyman Mottaghi
Izdano: (2010-01-01)

Correction to: The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
od: Zaoqian Zheng, et al.
Izdano: (2020-09-01)

Efficacy and safety of bisphosphonates on childhood osteoporosis secondary to chronic illness or its treatment: a meta-analysis
od: Huawei Zhao, et al.
Izdano: (2022-10-01)

Additional effects of herbal medicine combined with bisphosphonates for primary osteoporosis: a systematic review and meta-analysis
od: Young-Seo Yoo, et al.
Izdano: (2024-09-01)

Comparison of teriparatide and bisphosphonate in the treatment of postmenopausal osteoporosis: A meta-analysis
od: Yudong Li, et al.
Izdano: (2025-01-01)

Bisphosphonates and bone quality.
od: Pazianas, M, et al.
Izdano: (2014)

Evaluating the antifracture efficacy of bisphosphonates.
od: Pazianas, M, et al.
Izdano: (2009)

A reappraisal of generic bisphosphonates in osteoporosis.
od: Kanis, J, et al.
Izdano: (2012)

The use of bisphosphonates for the treatment and prevention of osteoporosis
od: O. A. Nikitinskaya, et al.
Izdano: (2022-08-01)

Atrial fibrillation and bisphosphonate therapy.
od: Pazianas, M, et al.
Izdano: (2010)

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
od: Pazianas, M, et al.
Izdano: (2007)

Oral Treatment With Bisphosphonates of Osteoporosis Does Not Increase the Risk of Severe Gastrointestinal Side Effects: A Meta-Analysis of Randomized Controlled Trials
od: Zsuzsa Réka Dömötör, et al.
Izdano: (2020-11-01)

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
od: Pazianas, M, et al.
Izdano: (2012)

Potential therapeutic effects of oral bisphosphonates on the intestine.
od: Pazianas, M, et al.
Izdano: (2011)

Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis
od: Jia Yang, et al.
Izdano: (2024-09-01)

Long-term consequences of osteoporosis therapy with bisphosphonates
od: Bárbara Gehrke, et al.
Izdano: (2023-11-01)

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
od: Pazianas, M
Izdano: (2013)

NE‐58025: A bisphosphonate with a low hydroxyapatite binding affinity
od: Michael Pazianas
Izdano: (2021-08-01)

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
od: Pazianas, M, et al.
Izdano: (2012)

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication
od: Bander Balkhi, et al.
Izdano: (2018-02-01)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
od: Yilin Zhu, et al.
Izdano: (2020-05-01)

Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced osteoporosis: a Bayesian network meta-analysis
od: Liang Dong, et al.
Izdano: (2024-01-01)

Atrial fibrillation and the use of oral bisphosphonates
od: Michael Pazianas, et al.
Izdano: (2011-03-01)

glucocorticoid osteoporosis; osteoporotic fracture; bisphosphonates; FRAX algorithm
od: Natalia Vladimirovna Toroptsova, et al.
Izdano: (2013-12-01)

Efficacy of Bisphosphonates for the Treatment of Osteoporosis in Patients with Multiple Sclerosis
od: İlke Coşkun Benlidayı, et al.
Izdano: (2015-08-01)

glucocorticoid osteoporosis; osteoporotic fracture; bisphosphonates; FRAX algorithm
od: Natalia Vladimirovna Toroptsova, et al.
Izdano: (2013-12-01)

Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders: comment on the article by Kling et al.
od: Pazianas, M
Izdano: (2010)

Atrial fibrillation and the use of oral bisphosphonates.
od: Pazianas, M, et al.
Izdano: (2011)